Novo Nordisk CEO to Step Down
Novo-Nordisk A/S said on Friday its CEO Lars Fruergaard Jorgensen will step down.
U.S.-listed shares of the company fell 3% in premarket trading.
"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024," Novo said in a statement.
Under his leadership, Novo Nordisk became a first-mover in the obesity and diabetes drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments.
Investors have however been concerned that Novo's first-to-market obesity drug is losing its lead to Eli Lilly, whose U.S. prescriptions for its Zepbound obesity shot have surpassed Wegovy since mid-March.
Jorgensen, who joined Novo Nordisk in 1991 and has been CEO since 2017, will continue as CEO for a transition period and a search for his successor is ongoing, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10